My Account | Shopping Cart | Contact
Trilink Biotech Logo

Oligonucleotides | mRNA & Long RNA | Nucleotides | CleanCap™ | CleanTag™ | CleanAmp™ | Custom Chemistry | GMP

OligoBuilder® | Nucleotides List | Stocked mRNA List | DNA Synthesis Reagents List | CleanAmp™ Products List


You are at: All > Nucleotides > Nucleotides by Structural Class > 5'-5' Dinucleoside Triphosphates (Cap Analogs)

N-7003
ARCA
Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G

ARCA

Extinction Coefficient: 21,000 Lmol-1cm-1 at 254 nm
Molecular Weight: 817.4 g/mol (free acid)
Molecular Formula: C22H32N10O18P3 (free acid)
Salt Form: NH4+
Purity Specification: ≥95% by AX-HPLC


Shipped at 100 mM in H2O.
1 µmole: 10 µL
5 µmole: 50 µL
10 µmole: 100 µL
 
Certificate(s) of Analysis
 

Trusted TriLink quality, exceptional price.
 
A key step in cellular mRNA processing is the addition of a 5’ cap structure, which is a 5'-5' triphosphate linkage between the 5' end of the RNA and a guanosine nucleotide. The cap is methylated enzymatically at the N-7 position of the guanosine to form mature mCAP.
 
When preparing synthetic mRNA, the cap is often added prior to use in order to stabilize the mRNA and significantly enhance translation. Using a 4:1 mixture of a cap analog to GTP in transcription reactions will cap 80% of the resulting mRNAs. If mCAP (pre-methylated CAP) is used, only half of the asymmetrical mCAP will insert in the functional orientation. ARCA can only insert in the correct orientation, resulting in mRNAs that are translated twice as efficiently. TriLink is the least expensive source of high quality ARCA. We also offer CAP and mCAP for more traditional capping reactions.
 



Email a Friend
Product Inquiry
    
Ready To Order?

Please select a size :
   1 µmole ($134.00)
   5 µmoles ($618.00)
   10 µmoles ($1,137.00)


 



Related Products :

Related Categories :


Reference(s)
Kenney SP, Meng XJ. Lysine Residues within the Human Ribosomal Protein S17 (RPS17) Sequence Naturally Inserted into the Viral Nonstructural Protein of a Unique Strain of Hepatitis E Virus are Important for Enhanced Virus Replication. J Virol. 2015 Jan 21
Lee K, Yu P, Lingampalli N, Kim HJ, Tang R, Murthy N.Peptide-enhanced mRNA transfection in cultured mouse cardiac fibroblasts and direct reprogramming towards cardiomyocyte-like cells.Int J Nanomedicine. 2015 Mar 6
Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 2015 Feb 5.
Guo XR, et al. PDX-1 mRNA-induced reprogramming of mouse pancreas-derived mesenchymal stem cells into insulin-producing cells in vitro. Clin Exp Med. 2014 Oct 28.
Wang Xiao, et al. Reprogramming human umbilical cord mesenchymal stromal cells to islet-like cells with the use of in vitro–synthesized pancreatic-duodenal homebox 1 messenger RNA. Volume 16, Issue 11, November 2014, Pages 1519–1527
Wang Y, Su HH, Yang Y, Hu Y, Zhang L, Blancafort P, Huang L. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther. 2013 Feb;21(2):358-67.
Uchida S, Itaka K, Uchida H, Hayakawa K, Ogata T, Ishii T, Fukushima S, Osada K, Kataoka K. In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle. PLoS One. 2013;8(2):e56220.
Johnsson P, Ackley A, Vidarsdottir L, Lui WO, Corcoran M, Grandér D, Morris KV. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol. 2013 Feb 24. doi: 10.1038/nsmb.2516.
Mandal PK, Rossi DJ. Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc. 2013 Feb 21;8(3):568-82.
Phua KK, Leong KW, Nair SK. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J Control Release. 2013 Jan 7. doi: 10.1016/j.jconrel.2012.12.029.
Warren L, Ni Y, Wang J, Guo X. Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. Sci Rep. 2012;2:657.
Anderson, B.R., Muramatsu, H., Jha, B.K., Silverman, R.H., Weissman, D., Kariko, K. Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L (2011) Nucleic Acids Research, EPub Aug
Anderson, B., Muramatsu, H., Nallagatla, S.R., Bevilacqua, P.C., Sansing, L.H., Weissman, D. & Kariko, K. Incorporation of pseudouridine into mRNA enhances translation by dimishing PKR activation (2010) Nucleic Acids Research, 38(17): 5884-5892.
Warren et al., Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA, Cell Stem Cell (2010), doi:10.1016/j.stem.2010.08.012.
Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modifiation and the Evolutionary Origin of RNA (2005). Immunity, 23(2), 165-175.
Peng ZH, Sharma V, Singleton SF, Gershon PD. Synthesis and application of a chain-terminating dinucleotide mRNA cap analog. (2002) Organic Letters. 4(2):161-4.
Konarska MM, Padgett RA, Sharp PA. Recognition of cap structure in splicing in vitro of mRNA precursors. (1984) Cell. 38(3):731-6.
Miura K. The cap structure in eukaryotic messenger RNA as a mark of a strand carrying protein information. (1981) Adv Biophys. 14:205-38.
Banerjee AK. 5'-terminal cap structure in eucaryotic messenger ribonucleic acids. (1980) Microbiol Rev. 44(2):175-205.
Rosenberg M, Paterson BM. Efficient cap-dependent translation of polycistronic prokaryotic mRNAs is restricted to the first gene in the operon. (1979) Nature. 21;279(5715):696-701.
Filipowicz W. Functions of the 5,-terminal m7G cap in eukaryotic mRNA. (1978) FEBS Lett. 96(1):1-11.
Zan-Kowalczewska M, Bretner M, Sierakowska H, Szczesna E, Filipowicz W, Shatkin AJ. Removal of 5'-terminal m7G from eukaryotic mRNAs by potato nucleotide pyrophosphatase and its effect on translation. (1977) Nucleic Acids Res. 4(9):3065-81.


 

 


  Twitter Twitter Facebook Facebook Linked In Linked In RSS RSS Google RSS  
© 2017 TriLink BioTechnologies, LLC | All Rights Reserved